More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the development of effective targeted therapies directed against RAS has lagged behind those more successful advancements in the field of therapeutic tyrosine kinase inhibitors targeting other oncogenes such as EGFR, ALK, and ROS1. The discoveries that (1) malignant RAS oncogenes differ from their wild-type counterparts by only a single amino acid change and (2) covalent inhibition of the cysteine residue at codon 12 of KRAS G12C in its inactive GDP-bound state resulted in effective inhibition of oncogenic RAS signaling and have catalyzed a dramatic shift in mindset toward KRAS-driven cancers. Although the development of allele-selective KRAS G12C inhibitors has changed a treatment paradigm, the clinical activity of these agents is more modest than tyrosine kinase inhibitors targeting other oncogene-driven cancers. Heterogeneous resistance mechanisms generally result in the restoration of RAS/mitogen-activated protein kinase pathway signaling. Many approaches are being evaluated to overcome this resistance, with many combinatorial clinical trials ongoing. Furthermore, because KRAS G12D and KRAS G12V are more prevalent than KRAS G12C , there remains an unmet need for additional therapeutic strategies for these patients. Thus, our current translational standing could be described as “the end of the beginning,” with additional discovery and research innovation needed to address the enormous disease burden imposed by RAS-mutant cancers. Here, we describe the development of KRAS G12C inhibitors, the challenges of resistance to these inhibitors, strategies to mitigate that resistance, and new approaches being taken to address other RAS-mutant cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Expression of the identified KRAS mutants was sufficient to confer resistance to KRAS G12C inhibitors in KRAS G12C cancer cells [49, 51, 60].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [60]
In the citing paper
“The genetic alterations identified in these studies are highly heterogeneous and may mediate therapeutic resistance via diverse mechanisms, such as changing inhibitor binding affinity, reactivating KRAS activity, and bypassing KRAS-mediated signaling [54, 56].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [56]
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Self-citationRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Reddy, E. P., Reynolds, R. K., Santos, E., & Barbacid, M. (1982) · Nature · doi:10.1038/300149a0 · Cited by 1,391
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Self-citationCo-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769
Isolation of a transforming sequence from a human bladder carcinoma cell line
Shih, C., & Weinberg, R. A. (1982) · Cell · doi:10.1016/0092-8674(82)90100-3 · Cited by 765
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change
Taparowsky, E., Suard, Y., Fasano, O., Shimizu, K., Goldfarb, M., & Wigler, M. (1982) · Nature · doi:10.1038/300762a0 · Cited by 703
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Goldfarb, M., Shimizu, K., Perucho, M., & Wigler, M. (1982) · Nature · doi:10.1038/296404a0 · Cited by 484
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
Targeting Alterations in the RAF–MEK Pathway
Yaeger, R., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 465
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Self-citationA model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335
Molina, J. R., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31506-9 · Cited by 324
Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02752 · Cited by 322
Self-citationSHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Robbins, K. C., & Barbacid, M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.9.2845 · Cited by 267
Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000706 · Cited by 235
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
Self-citationRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 166
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153
The National Lung Matrix Trial of personalized therapy in lung cancer
Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O’Rourke, N., Brewster, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2481-8 · Cited by 140
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31076-5 · Cited by 140
Self-citationKRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128
Self-citationMechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
Self-citationCell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico, A., De Giglio, A., Parisi, C., & Gelsomino, F. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.011 · Cited by 105
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0856 · Cited by 105
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
Li, C., Vides, A., Kim, D., Xue, J. Y., Zhao, Y., & Lito, P. (2021) · Science · doi:10.1126/science.abf1730 · Cited by 103
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155523 · Cited by 103
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 87
Zhang, B., Zhang, Y., Zhang, J., Liu, P., Jiao, B., Wang, Z., & Ren, R. (2021) · Advanced Science · doi:10.1002/advs.202100250 · Cited by 83
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Weiss, J., Yaeger, R. D., Johnson, M. L., Spira, A., Klempner, S. J., Barve, M. A., Christensen, J. G., Chi, A., Der-Torossian, H., Velastegui, K., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2093 · Cited by 73
Self-citationOu, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., McCoach, C., Wang, J. S., Gordon, M., Haura, E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.041 · Cited by 73
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Tran, T. H., Alexander, P., Dharmaiah, S., Agamasu, C., Nissley, D. V., McCormick, F., Esposito, D., Simanshu, D. K., Stephen, A. G., & Balius, T. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918164117 · Cited by 65
Self-citationTumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0170 · Cited by 53
Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578756 · Cited by 52
Pavan, A., Bragadin, A. B., Calvetti, L., Ferro, A., Zulato, E., Attili, I., Nardo, G., Maso, A. D., Frega, S., Menin, A. G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-674 · Cited by 49
Ho, C. S. L., Tüns, A. I., Schildhaus, H.-U., Wiesweg, M., Grüner, B. M., Hegedus, B., Schuler, M., Schramm, A., & Oeck, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.003 · Cited by 45
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 42
Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1046 · Cited by 34
Self-citationDrilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003665 · Cited by 31
Targeting KRAS in Non-Small Cell Lung Cancer
Corral de la Fuente, E., Olmedo Garcia, M. E., Gomez Rueda, A., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 30
Bendell, J. C., Ulahannan, S. V., Koczywas, M., Brahmer, J. R., Capasso, A., Eckhardt, S. G., Gordon, M. S., McCoach, C. E., Nagasaka, M., Ng, K., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31089-3 · Cited by 25
Nichols, R., Schulze, C., Bermingham, A., Choy, T., Cregg, J., Kiss, G., Marquez, A., Reyes, D., Saldajeno-Concar, M., Weller, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.035 · Cited by 23
Liu, Y., Wu, L., Lü, H., Wu, E., Ni, J., & Zhou, X. (2021) · Journal of Oncology · doi:10.1155/2021/2721466 · Cited by 7
Research works printed but not linked: 12
- Healy FM, Br J Pharmacol.
- Proulx-Rocray F, 2021, J Clin Oncol., 39
- Skoulidis F, 2021, J Clin Oncol., 39
- Brana I, 2021, J Clin Oncol., 39
- Hofmann MH, 2021, Cancer Res., 81
- Gort E, 2020, J Clin Oncol., 38
- Gandara D, 2021, Mol Cancer Ther., 20
- Ramalingam S, 2021, Mol Cancer Ther., 20
- Koltun E, 2021, Cancer Res., 81
- Krebs MG, 2021, Cancer Res., 81
- Ricciuti B, Clin Cancer Res.
- Boumelha J, 2022, Cancer Immunol Res., 10
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
“We hypothesized that, in contrast to mutant RAS-addicted tumor cells, normal cells have reduced levels and/or dependence on RAS-GTP and use homeostatic mechanisms to restore equilibrium following perturbation of RAS signaling (43, 44).”
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
“Loss of MET function through siRNA depletion of MET or by treatment with the MET inhibitor crizotinib restored sensitivity to sotorasib treatment both in vitro and in vivo [75].”
InfluentialTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 159
“Overcoming resistance to KRAS G12C inhibitors remains a challenge, prompting ongoing clinical trials that investigate combination therapies 12 .”
Metadata
- Authors
- Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R.
- Affiliations
- Sarah Cannon (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Manchester (GB)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 205-217
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280497507
- Cited by
- 44
- References
- 90
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 23 · 2023: 7 · 2022: 4
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C inhibitors, KRAS mutation, oncogenic Ras, drug resistance mechanisms, KRAS G12D, KRAS G12V, targeted cancer therapy, combination therapy
- MeSH terms
- Humans, Mutation, Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Genes, ras, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.